Cancer monitoring by aberrant promotor methylation of the transcription factor genes PAX5 alpha PAX5 beta, novel loop helix loop protein, novel gene 2, and beta 3 genes
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 9, 2004
app pub date -
Mar 25, 2004
filing date -
Oct 18, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
PAX5 alpha and PAX5 beta and other genes as markers for cancer detection. A PCR-based technique of methylated CpG island amplification, followed by representational difference analysis, for identifying genes methylated in human cancer. The genes PAX5 alpha and PAX5 beta, novel loop helix loop protein, and a novel gene 2, and beta3 genes when methylated serve as markers for detecting, monitoring, diagnosing and prognosticating breast, colon, and lung cancer in humans. Amplification methods, including primer sequences for methylation specific polymerase chain reaction, are disclosed.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully